Online inquiry

IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14023MR)

This product GTTS-WQ14023MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14023MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6499MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ14307MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ12604MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ8029MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ660MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ10176MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ6525MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ15251MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW